{"commentary":{"count":245,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":245},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03937635\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT03937635","nct_id":"NCT03937635","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03937635. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Patients receive daratumumab IV on days 1, 8, 15, and 22 of courses 1-2, days 1 and 15 of courses 3-6, and day 1 of courses 7-24. Patients also receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 in courses 1-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.","label":"Arm I (daratumumab, lenalidomide, dexamethasone)","type":"EXPERIMENTAL"},{"description":"Patients receive lenalidomide PO daily on days 1-21 and dexamethasone PO on days 1, 8, 15, and 22 of courses 1-12. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.","label":"Arm II (lenalidomide, dexamethasone)","type":"EXPERIMENTAL"}],"collaborators":["National Cancer Institute (NCI)"],"completion_date":{"date":"2029-12-31","type":"ESTIMATED"},"conditions":["Smoldering Plasma Cell Myeloma"],"enrollment":{"count":288,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Daratumumab","type":"BIOLOGICAL"},{"name":"Dexamethasone","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Quality-of-Life Assessment","type":"OTHER"},{"name":"Questionnaire Administration","type":"OTHER"}],"last_update":"2026-08-19","lead_sponsor":"ECOG-ACRIN Cancer Research Group","official_title":"Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2029-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival (OS)","timeFrame":"From randomization to death due to any cause, or censored at date last known alive, assessed up to 15 years"},{"measure":"Functional Assessment of Cancer Therapy-General (FACT-G) score","timeFrame":"Baseline to 24 cycles of treatment (each cycle is 28 days)"}],"references":[],"start_date":{"date":"2019-09-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma","url":"https://clinicaltrials.gov/study/NCT03937635"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03937635"}